NCT06173362View on ClinicalTrials.gov

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

May 31, 2027

Conditions
Advanced Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
Interventions
DRUG

Abiraterone

Given abiraterone

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Darolutamide

Given darolutamide

DRUG

Prednisone

Given prednisone

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mamta Parikh

OTHER